A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This clinical trial is designed to assess the safety, tolerability, and antitumor activity of Datopotamab Deruxtecan (Dato-DXd) combined with other anticancer agents or as monotherapy in participants with solid tumors.
Epistemonikos ID: d25ea3ef59a98377a9e7d54063556bc61823e1f2
First added on: Oct 23, 2026